The role of the prostaglandin D2 receptor, DP, in eosinophil trafficking

Journal of Immunology

Volumn 179, Issue 7, 2007, Pages 4792-4799

  Schratl, Petra ^a   Royer, Julia F ^a   Kostenis, Evi ^b   Ulven, Trond ^c   Sturm, Eva M ^a   Waldhoer, Maria ^a   Hoefler, Gerald ^a   Schuligoi, Rufina ^a   Lippe, Irmgard Th ^a   Peskar, Bernhard A ^a   Heinemann, Akos ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; PROSTAGLANDIN D2; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; RAMATROBAN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; LIGAND; PROSTAGLANDIN D;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; EOSINOPHIL; GUINEA PIG; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FEMUR; GENETICS; HUMAN; METABOLISM;

ANIMALS; BONE MARROW; CELLS, CULTURED; CHEMOTAXIS; EOSINOPHILS; FEMUR; GUINEA PIGS; HUMANS; LIGANDS; PROSTAGLANDINS D; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 49749119253     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.7.4792     Document Type: Article

References (52)

1. Schleimer, R. P., C. C. Fox, R. M. Naclerio, M. Plaut, P. S. Creticos, A. G. Togias, J. A. Warner, A. Kagey-Sobotka, and L. M. Lichtenstein. 1985. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J. Allergy Clin. Immunol. 76: 369-374.
2. Fujitani, Y., Y. Kanaoka, K. Aritake, N. Uodome, K. Okazaki-Hatake, and Y. Urade. 2002. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J. Immunol. 168: 443-449.
3. Kostenis, E., and T. Ulven. 2006. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. 12: 148-158.
4. 2 in anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C. Br. J. Pharmacol. 100: 761-766.
5. Nagata, K., H. Hirai, K. Tanaka, K. Ogawa, T. Aso, K. Sugamura, M. Nakamura, and S. Takano. 1999. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 459: 195-199.
6. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193: 255-261.
7. 2 are potent activators of human eosinophils. J. Immunol. 168: 3563-3569.
8. 2, causes eosinophil mobilization from the bone marrow and primes eosinophils for chemotaxis. J. Immunol. 170: 4752-4758.
9. Bohm, E., G. J. Sturm, I. Weiglhofer, H. Sandig, M. Shichijo, A. McNamee, J. E. Pease, M. Kollroser, B. A. Peskar, and A. Heinemann. 2004. 11-Dehydrothromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J. Biol. Chem. 279: 7663-7670.
10. Gervais, F. G., R. P. Cruz, A. Chateauneuf, S. Gale, N. Sawyer, F. Nantel, K. M. Metters, and G. P. O'Neill. 2001. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J. Allergy Clin. Immunol. 108: 982-988.
11. 2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J. Immunol. 175: 6531-6536.
12. 2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin. Exp. Allergy 34: 1283-1290.
13. Cosmi, L., F. Annunziato, M. I. G. Galli, R. M. E. Maggi, K. Nagata, and S. Romagnani. 2000. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur. J. Immunol. 30: 2972-2979.
14. 2, and selective DP1 and DP2 receptor agonists on pulmonary infiltration of eosinophils in Brown Norway rats. J. Pharmacol. Exp. Ther. 313: 64-69.
15. 2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J. Pharmacol. Exp. Ther. 312: 954-960.
16. 2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J. Immunol. 174: 3703-3708.
17. 2-like and eotaxin-like selective responses in eosinophils and basophils. J. Biol. Chem. 277: 26012-26020.
18. 2 receptor, CRTH2. J. Immunol. 168: 981-985.
19. 2 receptors DP and CRTH2 for treatment of inflammation. Curr. Top. Med. Chem. 6: 1427-1444.
20. Boie, Y., N. Sawyer, D. M. Slipetz, K. M. Metters, and M. Abramovitz. 1995. Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem. 270: 18910-18916.
21. Gerashchenko, D., C. T. Beuckmann, Y. Kanaoka, N. Eguchi, W. C. Gordon, Y. Urade, N. G. Bazan, and O. Hayaishi. 1998. Dominant expression of rat prostanoid DP receptor mRNA in leptomeninges, inner segments of photoreceptor cells, iris epithelium, and ciliary processes. J. Neurochem. 71: 937-945.
22. Nantel, F., C. Fong, S. Lamontagne, D. H. Wright, A. Giaid, M. Desrosiers, K. M. Metters, G. P. O'Neill, and F. G. Gervais. 2004. Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosa. Prostaglandins Other Lipid Mediat. 73: 87-101.
23. Wright, D. H., A. W. Ford-Hutchinson, K. Chadee, and K. M. Metters. 2000. The human prostanoid DP receptor stimulates mucin secretion in LS174T cells. Br. J. Pharmacol. 131: 1537-1545.
24. Woodward, D. F., S. B. Hawley, L. S. Williams, T. R. Ralston, C. E. Protzman, C. S. Spada, and A. L. Nieves. 1990. Studies on the ocular pharmacology of prostaglandin D2. Invest. Ophthalmol. Visual Sci. 31: 138-146.
25. Woodward, D. F., C. S. Spada, S. B. Hawley, L. S. Williams, C. E. Protzman, and A. L. Nieves. 1993. Further studies on ocular responses to DP receptor stimulation. Eur. J. Pharmacol. 230: 327-333.
26. Wheeldon, A., and C. J. Vardey. 1993. Characterization of the inhibitory prostanoid receptors on human neutrophils. Br. J. Pharmacol. 108: 1051-1054.
27. Rossi, A. G., J. M. Cousin, I. Dransfield, M. F. Lawson, E. R. Chilvers, and C. Haslett. 1995. Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem. Biophys. Res. Commun. 217: 892-899.
28. 2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J. Immunol. 170: 4943-4952.
29. 2: identification of products formed in vitro. J. Biol. Chem. 258: 11713-11718.
30. Arimura, A., K. Yasui, J. Kishino, F. Asanuma, H. Hasegawa, S. Kakudo, M. Ohtani, and H. Arita. 2001. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751. J. Pharmacol. Exp. Ther. 298: 411-419.
31. Matsuoka, T., M. Hirata, H. Tanaka, Y. Takahashi, T. Murata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi, Y. Aze, et al. 2000. Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013-2017.
32. Parkar, A., P. August, T. Kuntzweiler, M. A. Ardati, and N. Baskaran. 2005. Nucleic acid encoding a novel prostaglandin receptor protein and methods of use thereof. WO 2005-0662209 A1.
33. Sturm, G. J., R. Schuligoi, E. M. Sturm, J. F. Royer, D. Lang-Loidolt, H. Stammberger, R. Amann, B. A. Peskar, and A. Heinemann. 2005. 5-oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils. J. Allergy Clin. Immunol. 116: 1014-1019.
34. Palframan, R. T., P. D. Collins, T. J. Williams, and S. M. Rankin. 1998. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow. Blood 91: 2240-2248.
35. Arunlakshana, O., and H. O. Schild. 1959. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 14: 48-58.
36. 2-induced eosinophil migration in vitro. J. Pharmacol. Exp. Ther. 305: 347-352.
37. Giles, H., P. Leff, M. L. Bolofo, M. G. Kelly, and A. D. Robertson. 1989. The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol. 96: 291-300.
38. Sharif, N. A., J. Y. Crider, S. X. Xu, and G. W. Williams. 2000. Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J. Pharmacol. Exp. Ther. 293: 321-328.
39. Walch, L., C. Labat, J. P. Gascard, V. de Montpreville, C. Brink, and X. Norel. 1999. Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br. J. Pharmacol. 126: 859-866.
40. Whittle, B. J., S. Moncada, K. Mullane, and J. R. Vane. 1983. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins 25: 205-223.
41. 2 is a potent chemoattractant for human eosinophils that acts via a novel DP receptor. Blood 98: 1942-1948.
42. Kaneko, T., R. Alvarez, I. F. Ueki, and J. A. Nadel. 1995. Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. Cell. Signal. 7: 527-534.
43. 2 receptor CRTH2. Mol. Pharmacol. 68: 393-402.
44. Bousquet, J., P. Chanez, J. Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, P. Godard, et al. 1990. Eosinophilic inflammation in asthma. N. Engl. J. Med. 323: 1033-1039.
45. Humbles, A. A., C. M. Lloyd, S. J. McMillan, D. S. Friend, G. Xanthou, E. E. McKenna, S. Ghiran, N. P. Gerard, C. Yu, S. H. Orkin, and C. Gerard. 2004. A critical role for eosinophils in allergic airways remodeling. Science 305: 1776-1779.
46. Lee, J. J., D. Dimina, M. P. Macias, S. I. Ochkur, M. P. McGarry, K. R. O'Neill, C. Protheroe, R. Pero, T. Nguyen, S. A. Cormier, et al. 2004. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 305: 1773-1776.
47. Green, R. H., C. E. Brightling, S. McKenna, B. Hargadon, D. Parker, P. Bradding, A. J. Wardlaw, and I. D. Pavord. 2002. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360: 1715-1721.
48. Coleman, R. A., and R. L. Sheldrick. 1989. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br. J. Pharmacol. 96: 688-692.
49. 2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids 4: 21-28.
50. 2 and BW245C activation of human platelet adenylate cyclase. Br. J. Pharmacol. 96: 301-306.
51. Ogletree, M. L., D. N. Harris, R. Greenberg, M. F. Haslanger, and M. Nakane. 1985. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 234: 435-341.
52. Ulven, T., and E. Kostenis. 2005. Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J. Med. Chem. 48: 897-900.